MAP2K7 and neurofibromatosis type 1: Klesse Klesse LJ LJ Jordan Jordan JT JT Radtke Radtke HB HB The Use of MEK Inhibitors in Neurofibromatosis Type 1—Associated Tumors and Management of Toxicities The Use of MEK Inhibitors in Neurofibromatosis Type 1—Associated Tumors and Management of Toxicities Oncologist Oncologist 2020 2020 25 25 7 7 e1109 e1109 e1116 e1116 10.1634/theoncologist.2020-0069 10.1634/theoncologist.2020-0069 supplied-pmid 32272491?